Skip to content

Alan J. Korman

Yale New Haven Hospital

3 papers in the Anchorcite directory, published between 2012 and 2013, cited 25,134 times in total.

ORCID profile

Research topics

Frequent co-authors

Papers

  1. Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerNew England Journal of Medicine · 2012 · 12,793 citations

    BACKGROUND: Blockade of programmed death 1 (PD-1), an inhibitory receptor expressed by T cells, can overcome immune resistance. We assessed the antitumor activity and safety of BMS-936558, an antibody that specifically blocks PD-1. METHODS: We enrolled patients with advanced melanoma,…

  2. Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced CancerNew England Journal of Medicine · 2012 · 8,054 citations

    BACKGROUND: Programmed death 1 (PD-1) protein, a T-cell coinhibitory receptor, and one of its ligands, PD-L1, play a pivotal role in the ability of tumor cells to evade the host's immune system. Blockade of interactions between PD-1 and PD-L1 enhances…

  3. Nivolumab plus Ipilimumab in Advanced MelanomaNew England Journal of Medicine · 2013 · 4,287 citations

    BACKGROUND: In patients with melanoma, ipilimumab (an antibody against cytotoxic T-lymphocyte-associated antigen 4 [CTLA-4]) prolongs overall survival, and nivolumab (an antibody against the programmed death 1 [PD-1] receptor) produced durable tumor regression in a phase 1 trial. On the basis…

Metadata from OpenAlex (CC0).